Amplyx grabs $67M to fund a pivotal drive to the FDA with an anti-fungal aimed at a lethal threat
Amplyx Plarmaceuticals is prepping a move into a pivotal Phase II program for its anti-fungal drug with a sizable $67 million round in hand to pay for the two-year effort ahead. And it’s tackling a dangerous fungus with its broad-spectrum therapy that the CDC has characterized as a “catastrophic threat.”
Amplyx CEO Ciara Kennedy says that the San Diego-based biotech more than doubled its total raise before this round after finishing up the Phase I program. As the government has steadily upped the incentives it’s using to encourage development of drug-resistant infection fighters, lawmakers moved the goal post for her company up to Phase II — making this a “really interesting and exciting time.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
